A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder.

dc.contributor.author

Dawson, Geraldine

dc.contributor.author

Sun, Jessica M

dc.contributor.author

Baker, Jennifer

dc.contributor.author

Carpenter, Kimberly

dc.contributor.author

Compton, Scott

dc.contributor.author

Deaver, Megan

dc.contributor.author

Franz, Lauren

dc.contributor.author

Heilbron, Nicole

dc.contributor.author

Herold, Brianna

dc.contributor.author

Horrigan, Joseph

dc.contributor.author

Howard, Jill

dc.contributor.author

Kosinski, Andrzej

dc.contributor.author

Major, Samantha

dc.contributor.author

Murias, Michael

dc.contributor.author

Page, Kristin

dc.contributor.author

Prasad, Vinod K

dc.contributor.author

Sabatos-DeVito, Maura

dc.contributor.author

Sanfilippo, Fred

dc.contributor.author

Sikich, Linmarie

dc.contributor.author

Simmons, Ryan

dc.contributor.author

Song, Allen

dc.contributor.author

Vermeer, Saritha

dc.contributor.author

Waters-Pick, Barbara

dc.contributor.author

Troy, Jesse

dc.contributor.author

Kurtzberg, Joanne

dc.date.accessioned

2022-03-23T15:08:30Z

dc.date.available

2022-03-23T15:08:30Z

dc.date.issued

2020-07

dc.date.updated

2022-03-23T15:08:29Z

dc.description.abstract

Objective

To evaluate whether umbilical cord blood (CB) infusion is safe and associated with improved social and communication abilities in children with autism spectrum disorder (ASD).

Study design

This prospective, randomized, placebo-controlled, double-blind study included 180 children with ASD, aged 2-7 years, who received a single intravenous autologous (n = 56) or allogeneic (n = 63) CB infusion vs placebo (n = 61) and were evaluated at 6 months postinfusion.

Results

CB infusion was safe and well tolerated. Analysis of the entire sample showed no evidence that CB was associated with improvements in the primary outcome, social communication (Vineland Adaptive Behavior Scales-3 [VABS-3] Socialization Domain), or the secondary outcomes, autism symptoms (Pervasive Developmental Disorder Behavior Inventory) and vocabulary (Expressive One-Word Picture Vocabulary Test). There was also no overall evidence of differential effects by type of CB infused. In a subanalysis of children without intellectual disability (ID), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale, but the OR for improvement was not significant. Children without ID treated with CB showed significant improvements in communication skills (VABS-3 Communication Domain), and exploratory measures including attention to toys and sustained attention (eye-tracking) and increased alpha and beta electroencephalographic power.

Conclusions

Overall, a single infusion of CB was not associated with improved socialization skills or reduced autism symptoms. More research is warranted to determine whether CB infusion is an effective treatment for some children with ASD.
dc.identifier

S0022-3476(20)30334-6

dc.identifier.issn

0022-3476

dc.identifier.issn

1097-6833

dc.identifier.uri

https://hdl.handle.net/10161/24573

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

The Journal of pediatrics

dc.relation.isversionof

10.1016/j.jpeds.2020.03.011

dc.subject

Fetal Blood

dc.subject

Humans

dc.subject

Treatment Outcome

dc.subject

Blood Transfusion

dc.subject

Follow-Up Studies

dc.subject

Prospective Studies

dc.subject

Double-Blind Method

dc.subject

Communication

dc.subject

Language Tests

dc.subject

Child

dc.subject

Child, Preschool

dc.subject

Female

dc.subject

Male

dc.subject

Autism Spectrum Disorder

dc.title

A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder.

dc.type

Journal article

duke.contributor.orcid

Dawson, Geraldine|0000-0003-1410-2764

duke.contributor.orcid

Sun, Jessica M|0000-0001-8085-1013

duke.contributor.orcid

Carpenter, Kimberly|0000-0002-3838-798X

duke.contributor.orcid

Compton, Scott|0000-0003-2887-9582

duke.contributor.orcid

Franz, Lauren|0000-0003-4434-7500

duke.contributor.orcid

Kosinski, Andrzej|0000-0003-4151-5185

duke.contributor.orcid

Page, Kristin|0000-0001-9670-8828

duke.contributor.orcid

Troy, Jesse|0000-0001-5410-8146

duke.contributor.orcid

Kurtzberg, Joanne|0000-0002-3370-0703

pubs.begin-page

164

pubs.end-page

173.e5

pubs.organisational-group

Duke

pubs.organisational-group

Pratt School of Engineering

pubs.organisational-group

Sanford School of Public Policy

pubs.organisational-group

School of Medicine

pubs.organisational-group

Faculty

pubs.organisational-group

Sanford

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.organisational-group

Neurobiology

pubs.organisational-group

Biomedical Engineering

pubs.organisational-group

Pathology

pubs.organisational-group

Pediatrics

pubs.organisational-group

Radiology

pubs.organisational-group

Pediatrics, Hematology-Oncology

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Duke Global Health Institute

pubs.organisational-group

Duke Institute for Brain Sciences

pubs.organisational-group

Initiatives

pubs.organisational-group

Duke Innovation & Entrepreneurship

pubs.organisational-group

Pediatrics, Transplant and Cellular Therapy

pubs.publication-status

Published

pubs.volume

222

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
p366 Dawson.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
Description:
Published version